Clinical trials: Prostatic Neoplasms, Castration-Resistant
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with…
- Trial name
- NCT02257736
- Testing
- Apalutamide, Abiraterone acetate, Prednisone
- Where
- 173 sites in United States, Argentina and 14 more
- Volunteers
- 982 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostatic Neoplasms
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
- Trial name
- Galahad (NCT02854436)
- Testing
- Niraparib
- Where
- 110 sites in United States, Australia and 13 more
- Volunteers
- 289 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer Non-Metastatic, Castration-Resistant
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.
- Trial name
- ARAMIS (NCT02200614)
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 404 sites in United States, Argentina and 34 more
- Volunteers
- 1,509 people
- Sponsor
- Bayer
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted…
- Trial name
- SPLASH (NCT04647526)
- Testing
- [Lu-177]-PNT2002, Abiraterone, Enzalutamide
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 455 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Prostatic Neoplasms
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two…
- Trial name
- NCT00638690
- Testing
- Abiraterone acetate, Prednisone/prednisolone
- Where
- 127 sites in United States, Australia and 10 more
- Volunteers
- 1,195 people
- Sponsor
- Cougar Biotechnology, Inc.
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Prostate Cancer
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells. B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.
- Trial name
- NCT01804712
- Testing
- rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Christopher Kane
Prostate Cancer, Prostatic Neoplasms
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer.
- Trial name
- NCT00878436
- Testing
- Panobinostat, Bicalutamide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- NYU Langone Health
Metastatic Castration-resistant Prostate Cancer
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed…
- Trial name
- NCT05457257
- Testing
- olaparib, enzalutamide, abiraterone acetate
- Where
- 35 sites in China
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
This phase II trial investigates the effect of olaparib in treating patients with castration resistant prostate adenocarcinoma. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT04951492
- Testing
- Olaparib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Prostate Cancer
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
This is a single arm study of 11 men with treatment refractory metastatic Castrate Resistant Prostate Cancer (CRPC) who will receive temsirolimus IV at a dose of 25 mg weekly until progression.
- Trial name
- NCT00887640
- Testing
- Temsirolimus, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Prostatic Neoplasms
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3…
- Trial name
- NCT01934790
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 16 sites in United States, Finland and 5 more
- Volunteers
- 45 people
- Sponsor
- Bayer
Prostate Cancer
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic…
- Trial name
- NCT03556904
- Testing
- Ablative Radiation Therapy, Hormone therapy or chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Castration Resistant Prostate Cancer
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer)…
- Trial name
- PRESIDE (NCT02288247)
- Testing
- Enzalutamide, Docetaxel, Prednisolone
- Where
- 89 sites in Austria, Belgium and 14 more
- Volunteers
- 688 people
- Sponsor
- Astellas Pharma Europe Ltd.
Metastatic Castration Resistant Prostate Cancer
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy.
- Trial name
- NCT03641560
- Testing
- Enzalutamide, Androgen deprivation therapy (ADT)
- Where
- 8 sites in India
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Neoplasms
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta)…
- Trial name
- NCT02215096
- Testing
- GSK2636771, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline